Invitrogen Officials Say Acquisition Strategy, BioReliance Recovery Remain on Track | GenomeWeb

Invitrogen's plan to spend half a billion dollars on acquisitions in 2006 remains on track, Chairman and CEO Greg Lucier said during a conference call last week, despite what he views as higher premiums being paid for acquisition targets.

Lucier also said during the call, which followed the release of Invitrogen's first-quarter results, that the firm believes the BioReliance business, which has struggled over the last year, will recover and return to positive sales growth this year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A Karmagenes researcher has lost his position after reportedly admitting to data fabrication, according to Retraction Watch.

Two neuroscientists write in Nature News that solving the "reproducibility crisis" in science may require changing the requirements for publication.

In Nature this week: genomic analysis of prehistoric New Mexicans, a nanopore method for mapping DNA methylation, and more.

A new study finds that adding missing good bacteria to the skin microbiome of atopic dermatitis patients decreases Staphylococcus aureus colonization.